Grants for Independent school districts - Health

Research shows that HIV care must increasingly address the management of individuals with multiple coexisting diseases (p.357) such as infectious and chronic diseases, mental health and behavioral disorders, food insecurity, substance use, etc. Since individual diseases do not exist in a vacuum, neither does the management, or burden of disease on community well-being. In response, syndemic theory and approaches are used to (1) increase the focus on co-occurring and interacting disease and social conditions that exacerbate health inequities, and (2) advance the evidence base for effective approaches to assess, monitor, and intervene with respect to these co-occurring and interacting factors for optimal outcomes in HIV treatment and care. The purpose of this project is to design, implement, and evaluate innovative comprehensive interventions part of an integrated treatment plan , using a syndemic approach to address co-occurring and interacting conditions of HIV, substance use disorder, intimate partner violence (IPV), and other social determinants of health that impact health outcomes of racial and ethnic minorities with HIV.

This program provides financial support to local governments in Illinois for community development and resilience projects in areas impacted by the closure or reduced operation of fossil fuel power plants, coal mines, or nuclear facilities.

The purpose of the NCCC program is to provide rapid, expert, and culturally competent clinical consultation and advice to health care team members on a wide range of HIV and HIV-related topics. The NCCC, using a combination of various funding sources, provides services through telephone-based warmlines, a hotline, and internet-based educational consultation services in the following clinical areas: General HIV prevention, care, and treatment, including diagnosis, testing, and antiretroviral therapy. Pre-exposure prophylaxis (PrEP). Post-exposure prophylaxis (PEP). Treatment and management of Hepatitis B and C and HIV coinfections. Treatment and management of substance use disorders in people with or at risk for HIV. Perinatal HIV care and management. The NCCC provides expert consultation that demonstrates an understanding of the HIV epidemic in a variety of locations including: EHE jurisdictions. Rural areas. Areas disproportionately impacted by substance use disorders including opioid use disorder, and other co-morbidities. Communities where a large number of the people with HIV identify as a non-white racial or ethnic group. The goals for the NCCC align with those of the RWHAP Part F AETC Program, which are: Goal 1: Expand the number of health care team members providing HIV care and prevention services, including providers with different backgrounds or experiences. Goal 2: Expand the ability of health care team members to provide effective HIV care and prevention services. Goal 3: Improve health equity by integrating HIV care and prevention in primary care and other health care settings that provide services to underserved populations. Goal 4: Enhance the capacity of the AETC Program to train health care team members to serve people at risk for or with HIV.

This funding opportunity is designed to support clinical centers conducting research on the development of Type 1 diabetes following episodes of acute pancreatitis, focusing on understanding its causes, progression, and risk factors in a diverse population.

The Catalyze Product Definition Funding Opportunity Announcement (FOA) offers early-stage financial support for the discovery and study of potential treatments for heart, lung, blood, and sleep diseases, with the goal of progressing these projects to a stage where they qualify for the NHLBI Catalyze Preclinical program or secure funding from other sources for further development.

This funding opportunity supports researchers exploring the biological mechanisms of bladder cancer to improve understanding and treatment of this prevalent disease.

This funding opportunity supports innovative research projects on brain and nervous system disorders, encouraging collaboration between scientists in the U.S. or upper-middle-income countries and those in low- and middle-income countries to improve health outcomes throughout life.

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA

This funding opportunity provides financial support for innovative research projects aimed at understanding the neurological and mental health effects of chronic illnesses linked to infections, such as Long COVID and chronic fatigue syndrome, encouraging studies that explore their underlying mechanisms.

The purpose of the NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00) is to support a defined pathway across career stages for talented graduate students from diverse backgrounds, including those from groups underrepresented in biomedical, clinical, behavioral and social sciences. This two-phased award will facilitate completion of a doctoral dissertation (F99) and transition to a strong postdoctoral research position (K00) focused on the scientific, medical, ethical, social and/or legal areas of genomics research. It is anticipated that successful completion of this phased award program will have provided students sufficient scientific and career development activities to set them on the path to becoming independent genomics researchers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor.

This grant provides funding for educational programs that support individuals from diverse backgrounds to pursue careers in substance use and addiction research through hands-on research experiences and skills development.

This grant provides funding for research aimed at understanding and addressing schizophrenia and related disorders in individuals aged 35 and older, targeting a wide range of eligible applicants including universities, nonprofits, and businesses.

This funding opportunity provides financial support for diverse doctoral students conducting research on aging and related health issues, helping to cultivate a more inclusive scientific workforce.

This funding opportunity supports researchers exploring innovative strategies to achieve long-lasting HIV remission at the start of antiretroviral therapy, focusing on basic and preclinical studies rather than clinical trials.

This funding opportunity supports Arizona-based institutions conducting clinical research on ibogaine's potential therapeutic uses for neurological diseases, encouraging collaboration among academic, nonprofit, and private sectors.

This funding opportunity announcement (FOA) invites research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider the companion FOA TEMP-14931 "Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01 Basic Experimental Studies with Humans Required)".

This notice announces the opportunity to apply for funding under the Center for Maternal and Child Health Medicaid Partnerships program. The purpose of the Center for Maternal and Child Health Medicaid Partnerships is to strengthen collaboration between state Medicaid, Childrens Health Insurance Program (CHIP), and Title V Maternal and Child Health Services Block Grant (Title V) programs and advance innovative financing strategies that improve outcomes and reduce health disparities for maternal and child health (MCH) populations. The award recipient will build knowledge and shared priorities between state Medicaid, CHIP, and Title V programs and provide one-to-one, state-specific tailored capacity-building assistance directly to state Medicaid, CHIP, and Title V programs to support MCH. Support will include: (1) engaging state Title V, Medicaid, and CHIP programs to identify shared priorities and foster a common understanding of needs, opportunities, and best practices; (2) one-to-one, state-specific, tailored assistance to advance MCH financing; (3) support the development of innovative collaborative models leveraging HRSA, CHIP, and Medicaid funding, and (4) one-to-one capacity-building assistance to advance interagency agreements required by statute.

This funding opportunity provides $3.5 million over five years to organizations that will create a national resource hub for improving healthcare access and outcomes in rural communities across the United States.

This funding opportunity supports institutions in training clinical scientists focused on cancer research, enabling them to lead or participate in clinical trials as part of their career development.

(Reissue PAR-21-058). The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological diseases and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of biomarker measurements within the clinical population of interest to establish the positive and negative predictive values of the candidate biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.